Aberdeen Group plc Takes Position in Fulcrum Therapeutics, Inc. $FULC

Key Points

• Aberdeen Group plc has acquired a new stake in Fulcrum Therapeutics with approximately $404,000 invested in 58,696 shares, representing about 0.11% ownership.
• Fulcrum Therapeutics stock recently opened at $8.99, down 3.2%, and has a 52-week range from $2.32 to $9.89.
• Analysts have set a consensus price target of $9.60 for Fulcrum Therapeutics, with ratings varying from "Strong Buy" to "Sell."

Aberdeen Group plc acquired a new stake in Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 58,696 shares of the company's stock, valued at approximately $404,000. Aberdeen Group plc owned about 0.11% of Fulcrum Therapeutics as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of FULC. Y Intercept Hong Kong Ltd bought a new position in Fulcrum Therapeutics in the 1st quarter valued at $92,000. XTX Topco Ltd bought a new position in Fulcrum Therapeutics in the 1st quarter valued at $144,000. Invesco Ltd. grew its position in Fulcrum Therapeutics by 186.1% in the 1st quarter. Invesco Ltd. now owns 85,767 shares of the company's stock valued at $247,000 after acquiring an additional 55,791 shares during the last quarter. Virtu Financial LLC bought a new position in Fulcrum Therapeutics in the 1st quarter valued at $39,000. Finally, Nuveen LLC bought a new position in Fulcrum Therapeutics in the 1st quarter valued at $441,000. Institutional investors own 89.83% of the company's stock.

Fulcrum Therapeutics Stock Down 3.2%

Shares of Fulcrum Therapeutics stock opened at $8.99 on Friday. The firm's 50 day moving average price is $7.68 and its 200-day moving average price is $6.56. Fulcrum Therapeutics, Inc. has a 52-week low of $2.32 and a 52-week high of $9.89. The company has a market cap of $486.27 million, a P/E ratio of -7.37 and a beta of 2.93.

Fulcrum Therapeutics (NASDAQ:FULC - Get Free Report) last issued its quarterly earnings data on Tuesday, July 29th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.29) by $0.01. As a group, equities research analysts forecast that Fulcrum Therapeutics, Inc. will post -0.16 EPS for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have commented on FULC. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Fulcrum Therapeutics in a research report on Wednesday, October 8th. Royal Bank Of Canada increased their price target on Fulcrum Therapeutics from $4.00 to $5.00 and gave the stock a "sector perform" rating in a research report on Wednesday, July 30th. HC Wainwright raised Fulcrum Therapeutics from a "neutral" rating to a "buy" rating and increased their price target for the stock from $4.00 to $12.00 in a research report on Tuesday, July 29th. Finally, Wall Street Zen raised Fulcrum Therapeutics from a "sell" rating to a "hold" rating in a research report on Friday, September 26th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $9.60.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.

Want to see what other hedge funds are holding FULC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.